Trending...
- "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
- Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
RALEIGH N.C. & DURHAM, N.C.--(BUSINESS WIRE)--NovaQuest Private Equity ("NovaQuest") today announced its strategic growth equity investment in Pro-ficiency, LLC ("Pro-ficiency"), a leading provider of tech-enabled training and compliance solutions for clinical trial investigators and site staff.
Based in Durham, NC, Pro-ficiency provides innovative, virtual simulation training and HR compliance solutions for clinical trials, supported by original content creation and analytics services. Leading pharmaceutical companies engage Pro-ficiency to deploy customized, study-specific training solutions that improve learning retention and strengthen compliance among investigators and site staff. The company's platform also provides sponsors and CROs with real-time analytics that help to predict and avoid study errors and protocol violations, ultimately reducing the time, cost, and failure points of clinical trials. This integrated suite of services provides a compelling value proposition to its pharmaceutical customers.
"Pro-ficiency is excited to partner with NovaQuest, a firm with unparalleled global pharma and life sciences relationships and a proven track record of successfully supporting market-leading businesses in their next phase of growth," said David Hadden, Co-Founder of Pro-ficiency. "With NovaQuest's growth equity investment, Pro-ficiency is well-funded to continue changing the paradigm of clinical trial training."
More on ncarol.com
"Our customers are developing innovative products that require rigorous compliance across increasingly complex and global trials," said JoAnne Schaberick, Co-Founder of Pro-ficiency. "NovaQuest's expertise in life sciences and clinical trials will be invaluable as we continue to expand our team and offering to consistently surpass expectations and meet the needs of our valued customers."
"Dave and JoAnne are pioneers in the use of simulation-based training to improve healthcare. They have done an outstanding job developing a platform that addresses a critical, unmet need for better clinical trial training solutions," said Michael Sorensen, Partner at NovaQuest. "We look forward to supporting the Pro-ficiency team as it meets unprecedented demand for its mission-critical clinical trial training solutions."
Wyrick Robbins served as legal advisor to Pro-ficiency, and Smith Anderson served as legal advisor to NovaQuest. Deal terms were not announced.
About Pro-ficiency:
Pro-ficiency is a leading provider of tech-enabled training and compliance solutions for clinical trials. The Company provides a comprehensive suite of services, including a turn-key offering of customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. For more information, please visit www.pro-ficiency.com.
More on ncarol.com
About NovaQuest Private Equity:
NovaQuest Private Equity is a leading investor in technology and services companies in the life sciences and healthcare sectors. NovaQuest was formed in 2000 with the vision of building an investment platform to provide strategic capital and operational leverage in partnership with strong management teams. The investment team consists of highly seasoned operational and investment professionals with significant investment experience and deep life science and healthcare expertise. Furthermore, NovaQuest benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing, and growing NovaQuest portfolio companies and investments. For more information, please visit www.novaquest.com.
Based in Durham, NC, Pro-ficiency provides innovative, virtual simulation training and HR compliance solutions for clinical trials, supported by original content creation and analytics services. Leading pharmaceutical companies engage Pro-ficiency to deploy customized, study-specific training solutions that improve learning retention and strengthen compliance among investigators and site staff. The company's platform also provides sponsors and CROs with real-time analytics that help to predict and avoid study errors and protocol violations, ultimately reducing the time, cost, and failure points of clinical trials. This integrated suite of services provides a compelling value proposition to its pharmaceutical customers.
"Pro-ficiency is excited to partner with NovaQuest, a firm with unparalleled global pharma and life sciences relationships and a proven track record of successfully supporting market-leading businesses in their next phase of growth," said David Hadden, Co-Founder of Pro-ficiency. "With NovaQuest's growth equity investment, Pro-ficiency is well-funded to continue changing the paradigm of clinical trial training."
More on ncarol.com
- AI Real Estate Company Quietly Building a National Powerhouse: reAlpha Tech Corp. (N A S D A Q: AIRE)
- Inkdnylon Expands National Uniform Embroidery Services
- Appliance EMT Expands Appliance Repair Services to Portland, OR and Vancouver, WA
- Next Week: The World's Best Young Pianists Arrive in Music City for the 2025 Nashville International Chopin Piano Competition
- Revenue Optics Builds Out Its Dedicated Sales Recruiting Firm with Strategic Addition of Christine Schafer
"Our customers are developing innovative products that require rigorous compliance across increasingly complex and global trials," said JoAnne Schaberick, Co-Founder of Pro-ficiency. "NovaQuest's expertise in life sciences and clinical trials will be invaluable as we continue to expand our team and offering to consistently surpass expectations and meet the needs of our valued customers."
"Dave and JoAnne are pioneers in the use of simulation-based training to improve healthcare. They have done an outstanding job developing a platform that addresses a critical, unmet need for better clinical trial training solutions," said Michael Sorensen, Partner at NovaQuest. "We look forward to supporting the Pro-ficiency team as it meets unprecedented demand for its mission-critical clinical trial training solutions."
Wyrick Robbins served as legal advisor to Pro-ficiency, and Smith Anderson served as legal advisor to NovaQuest. Deal terms were not announced.
About Pro-ficiency:
Pro-ficiency is a leading provider of tech-enabled training and compliance solutions for clinical trials. The Company provides a comprehensive suite of services, including a turn-key offering of customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. For more information, please visit www.pro-ficiency.com.
More on ncarol.com
- Hydrofast Elevates the Holiday Season: The C100 Countertop RO System Merges Smart Tech with Wellness for the Perfect Christmas Gift
- Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
- Flower City Tattoo Convention Draws Record Attendance in Rochester, NY
- Carolina Cabinet Pros Earns Repeat Honor with Prestigious 2025 Angi's Super Service Award
- KIKO NATION TOKEN (Official Release)
About NovaQuest Private Equity:
NovaQuest Private Equity is a leading investor in technology and services companies in the life sciences and healthcare sectors. NovaQuest was formed in 2000 with the vision of building an investment platform to provide strategic capital and operational leverage in partnership with strong management teams. The investment team consists of highly seasoned operational and investment professionals with significant investment experience and deep life science and healthcare expertise. Furthermore, NovaQuest benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing, and growing NovaQuest portfolio companies and investments. For more information, please visit www.novaquest.com.
Filed Under: Business
0 Comments
Latest on ncarol.com
- Orim Link Inc. Announces Official Launch, Bringing Modern Business Technology Solutions to Charlotte
- FittingPros Launches Industry's First Data-Driven Golf Club Fitting Directory
- Take Control of Your Color Matching with Boston Industrial Solutions' Newly Expanded Natron® UVPX Series Ink Colors
- "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
- Kaufman Development Breaks Ground on Detroit Micro Data Center, Expanding Its National AI Platform
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- Top10Christmas.co.uk Releases the UK Christmas Toy Trends 2025 Report
- Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
- LocaXion and Asseco CEIT Announce First-to-Market RTLS-Driven Digital Twin Platform for Healthcare, Manufacturing, and Logistics
- Slotozilla Launches New Report on How AI Is Reshaping Careers and Society
- High Rise: Path to Nowhere (2022) — A High-Stakes Thriller Filmed in Charlotte, North Carolina
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- 15,000+ Fans Expected at the 2026 BIG HBCU Southern Classic Battle of the Bands in Charlotte
- Explosive Growth in U.S. Cryptocurrency Cloud Mining Sets The Stage for New Platform Launch with Daily Rewards in a Transparent Revenue-Share Model
- Qtex Cierra Ronda de $7 Millones para Estandarizar la Banca Transfronteriza en los Mercados Emergentes de Latinoamérica
- America's Most Festive Garages Wanted for Garage.com's 2025 Holiday Contest
- Railinc Launches RIGIS Routing+Mileage Application to Provide Accurate & Comprehensive Rail Routing
- FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough